Global Kidney Disease Drugs Market

1. Summary

The Global Kidney Disease Drugs Market was valued at $15.8 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 6.2% CAGR, to an estimated market size of $21.3 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global kidney disease drugs market comprises pharmaceutical interventions specifically designed to manage, slow the progression of, and treat chronic kidney disease (CKD), acute kidney injury (AKI), and end-stage renal disease (ESRD). The scope includes various drug classes such as SGLT-2 inhibitors, ACE inhibitors, Angiotensin-II Receptor Blockers (ARBs), erythropoiesis-stimulating agents (ESAs), and phosphate binders, while excluding medical devices, dialysis hardware, and surgical procedures.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Kidney Disease Drugs Market in the period 2025-30:

• The rising global prevalence of diabetes and hypertension remains the primary driver for chronic kidney disease progression.
• Rapid adoption of SGLT-2 inhibitors like Jardiance and Farxiga is transforming the standard of care for renal protection.
• Increased focus on early detection through novel biomarkers such as KIM-1 and NGAL is expanding the treatable patient pool.
• The growing geriatric population is significantly increasing the demand for long-term pharmacological management of renal decline.
• Pharmaceutical R&D is shifting toward cardiorenal metabolic syndrome to address the high comorbidity between heart and kidney failure.
• Emerging GLP-1 receptor agonists are showing significant clinical promise in reducing the risk of kidney disease progression.
• Expansion of healthcare infrastructure in emerging markets like China and India is driving higher diagnosis and treatment rates.

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments: